I suggest you look at the cohort 2 and 3 result to see the efficacy, Ph1 firstly is designed to demonstrate safety and Ph2 to demonstrate efficacy so them seeing any efficacy in Ph1 especially so early is very rare so what efficacy aren't you seeing????
Ann: VAXINIA and HER-Vaxx featured at the AACR Annual Meeting, page-246
-
- There are more pages in this discussion • 59 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $373.3M | |||
| Open | High | Low | Value | Volume |
| 5.1¢ | 5.2¢ | 4.9¢ | $1.384M | 27.31M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 1302118 | 5.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.2¢ | 528865 | 4 |
View Market Depth
| Last trade - 16.10pm 03/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |